Summary
Mismatch DNA repair deficiency is associated with resistance to certain major groove alkylating agents including methylating agents and cisplatin. We have now studied the relevance of mismatch repair alterations to the cytotoxicity induced by drugs which alkylate N3 adenines in the minor groove of DNA. We have used the mismatch repair defective human colocarcinoma cell line HCT-116 which has a mutation in the hMLH1 gene, and a subline where hMLH1 expression is restored by chromosome 3 transfer (HCT-116+ch3). We have tested three alkylating minor groove binders (tallimustine, carzelesin and CC1065) and one non-covalent minor groove binder (PNU 151807). The HCT-116+ch3 subline was more sensitive than the parental line to the treatment with the three alkylating minor groove binders, while the non-alkylating compound had a similar activity in both cell lines. Further support for mismatch repair being involved in sensitivity of the minor groove alkylators is that two cisplatin-resistant sublines of the human ovarian adenocarcinoma cell line A2780 (A2780/CP70 and A2780/MCP-1) are defective in hMLH1 expression and are more resistant to these agents than the parental mismatch repair proficient cells. Furthermore, the restoration of hMLH1 activity in the A2780/CP70 cell line, by introduction of chromosome 3, was associated with an increased sensitivity to the three alkylating minor groove binders. Again, the non-covalent minor groove binder was equally effective in mismatch repair deficient and proficient clones. The data indicate that mismatch repair deficiency mediated by loss of hMLH1 expression is associated not only with drug-resistance to major groove binders, but also to minor groove binders. However, loss of mismatch repair does not mediate resistance to the non-covalent minor groove binder PNU 151807.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aebi, S., Kurdi-Hadar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., Fishel, R. & Howell, S. B. (1996). Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087–3090.
Aebi, S., Fink, D., Gordon, R., Ki Kim, H., Zheng, H., Fink, J. L. & Howell, S. B. (1997). Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 3: 1763–1767.
Anthoney, D. A., McIlwrath, A. J., Gallagher, W. M., Edlin, A. R. & Brown, R. (1996). Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 56: 1374–1381.
Branch, P., Aquilina, A., Bignami, M. & Karran, P. (1993). Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362: 652–654.
Branch, P., Hampson, R. & Karran, P. (1995). DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 55: 2304–2309.
Broggini, M., Erba, E., Ponti, M., Ballinari, D., Geroni, C., Spreafico, F. & D’Incalci, M. (1991). Selective DNA interaction of the novel distamycin derivative FCE24517. Cancer Res 51: 199–204.
Broggini, M., Coley, H. M., Mongelli, N., Pesenti, E., Wyatt, M. D., Hartley, J. A. & D’Incalci, M. (1995). DNA sequence-specific adenine alkylation by the novel antitumor drug tallumustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Res 23: 81–87.
Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., Van Der Zee Age & Anthoney, D. A. (1997). hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15: 45–52.
D’Alessio, R., Geroni, C., Biasoli, G., Pesenti, E., Grandi, M. & Mongelli, N. (1994). Structure-activity relationship of novel distamycin A derivatives: synthesis and antitumor activity. Bioorganic Med Chem Lett 4: 1467–1472.
D’Incalci, M. & Sessa, C. (1997). DNA minor groove binding ligands: a new class of anticancer agents. Exp Opin Invest Drugs 6: 875–884.
Damia, G., Imperatori, L., Citti, L., Mariani, L. & D’Incalci, M. (1996a). 3-methyladenine-DNA-glycosylase and O6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines. Br J Cancer 73: 861–865.
Damia, G., Imperatori, L., Stefanini, M. & D’Incalci, M. (1996b). Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anticancer agents. Int J Cancer 66: 779–783.
Drummond, J. T., Anthoney, D. A., Brown, R. & Modrich, P. (1996). Cisplatin and adriamycin resistance are associated with MutLa and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 271: 19645–19648.
Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehmè, A., Christen, R. D. & Howell, S. B. (1996). The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881–4886.
Fink, D., Zheng, H., Nebel, S., Norris, P. S., Aebi, S., Lin, T. P., Nehmè, A., Christen, R. D., Haas, M., Macleod, C. L. & Howell, S. B. (1997). In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57: 1841–1845.
Fishel, R. & Kolodner, R. D. (1995). Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 5: 382–395.
Ghielmini, M., Bosshard, G., Capolongo, L., Geroni, M. C., Pesenti, E., Torri, V., D’Incalci, M., Cavalli, F. & Sessa, C. (1997). Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer 75: 878–883.
Hurley, L. H., Reynolds, V. L., Swenson, D. H., Petzold, G. L. & Scahill, T. A. (1984). Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science 226: 843–844.
Karran, P. & Bignami, M. (1994). DNA damage tolerance, mismatch repair and genome instability. Bioessays 16: 833–839.
Karran, P. & Hampson, R. (1996). Genomie instability and tolerance to alkylating agents. Cancer Surv 28: 69–85.
Koi, M., Umar, A., Chauhan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A. & Boland, C. R. (1994). Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54: 4308–4312.
Li, L. H., Dekoning, T. F., Kelly, R. C., Krueger, W. C., McGovren, J. P., Padbury, G. E., Petzold, G. L., Wallace, T. L., Ouding, R. J., Prairie, M. D. & Gebhard, I. (1992). Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res 52: 4904–4913.
Marchini, S., Cozzi, P., Beria, I., Geroni, C., Capolongo, L., D’Incalci, M. & Broggini, M. (1998). Sequence specific alkylation of novel tallimustine derivatives. Anti-Cancer Drug Design 13: 193–205.
Martin, D. G., Biles, C., Gerpheide, S. A., Hanka, L. J., Krueger, W. C., McGovren, J. P., Mizsak, S. A., Neil, G. L., Stewart, J. C. & Visser, J. (1981). CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity. J Antibiot Tokyo 34: 1119–1125.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Colella, G., Marchini, S., D’Incalci, M. et al. Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Br J Cancer 80, 338–343 (1999). https://doi.org/10.1038/sj.bjc.6690360
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690360
Keywords
This article is cited by
-
Paclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype
British Journal of Cancer (2007)
-
Brostallicin (PNU-166196) – a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells
British Journal of Cancer (2003)